Istamet is a pharmaceutical agent formulated as a fixed-dose combination of vildagliptin and metformin for the treatment of type 2 diabetes mellitus. Its therapeutic purpose is to lower blood glucose levels by enhancing the activity of incretin hormones that stimulate insulin secretion and suppress glucagon release. The medication works by inhibiting the enzyme dipeptidyl peptidase-4, thereby preventing the degradation of incretin peptides such as glp-1 and gip, which leads to increased insulin release and reduced hepatic glucose production. Pharmacodynamically, the inhibition results in prolonged elevation of active incretin levels, improving postprandial glucose control, while pharmacokinetically the drug is absorbed orally, reaches maximal plasma concentrations within a few hours, and is cleared primarily through renal excretion. Clinically, the combined effect of increased insulin secretion and decreased glucagon action translates into a modest reduction in fasting and postprandial glucose concentrations without causing significant hypoglycemia when used alone. Overall, the mechanism of Istamet involves enhancing endogenous incretin signaling to achieve better glycemic control in patients with type 2 diabetes.

Istamet is a combination medication that contains metformin and glimepiride. It is used to manage blood glucose levels in patients with type 2 diabetes. The drug works by enhancing the body's response to insulin and reducing hepatic glucose production. Metformin decreases hepatic gluconeogenesis and improves insulin sensitivity. Glimepiride stimulates pancreatic beta cells to increase insulin secretion. Together they help lower fasting and postprandial blood sugar concentrations. By targeting multiple pathways the medication provides more effective glycemic control than either agent alone. This dual mechanism illustrates how complementary actions can achieve therapeutic goals in diabetes management.

The most common side effects are generally mild and include headache fatigue and nausea. Headache often appears during the first few days of treatment. Fatigue may be felt as a reduction in energy levels. Nausea can cause a sensation of stomach discomfort. Dizziness sometimes leads to a light-headed feeling. Dry mouth reduces saliva production temporarily. Mild stomach upset may occur without requiring medical attention.

Common side effects of many medications include mild gastrointestinal discomfort. Headaches are frequently reported by users of certain treatments. Fatigue can occur as the body adjusts to a new regimen. Dizziness or lightheadedness may be experienced during the initial period. Some individuals notice skin reactions such as rash or itching. Changes in taste or appetite are also observed in a minority of cases. Rarely, mild fever or chills may appear as a response to therapy. These effects are generally transient and resolve without intervention.